Profound MedicalPROF -1.02%73 Piotroski F-Score is 4 as of Jul. 07, 2026, which is at its 10-year median of 4.00. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 808 Medical Devices & Instruments companies, Profound Medical ranks worse than 56.68% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Profound Medical has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Profound Medical's Piotroski F-Score or its related term are showing as below:
PROF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 5
Current: 4
During the past 12 years, the highest Piotroski F-Score of Profound Medical was 5. The lowest was 2. And the median was 4.
Profound Medical (NAS:PROF) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Profound Medical Piotroski F-Score Related Terms
Profound Medical Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Profound Medical's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROF vs ABT, SYK, MDT: Piotroski F-Score Comparison
For the Medical Devices subindustry, Profound Medical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Profound Medical's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Profound Medical's current Net Income (TTM) was -38.90.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Profound Medical's return on assets of this year was -0.63912986. Profound Medical's return on assets of last year was -0.55688195.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Profound Medical's gearing of this year was 0.04760212. Profound Medical's gearing of last year was 0.08231611.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Profound Medical's current ratio of this year was 6.55510512. Profound Medical's current ratio of last year was 11.31482531.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Profound Medical's number of shares in issue this year was 36.298. Profound Medical's number of shares in issue last year was 30.042.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Profound Medical's gross margin of this year was 0.71074732. Profound Medical's gross margin of last year was 0.67644579.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Profound Medical's asset turnover of this year was 0.3091154. Profound Medical's asset turnover of last year was 0.20671988.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
0
+
1
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Profound Medical has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Profound Medical (PROF) has a Piotroski F-Score of 4 as of Jul. 07, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Profound Medical and its competitors. This is near median its historical median of 4.00. Over the past decade, Profound Medical's Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Profound Medical ranks #458 out of 808 companies in the Medical Devices & Instruments industry, placing it in the top 56.7%.
Is Profound Medical's Piotroski F-Score too high?
Profound Medical's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Profound Medical's value of 4 is 20% below this industry median. Based on the distribution chart, Profound Medical ranks #458 out of 808 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #458 out of 808 companies for Piotroski F-Score. This places Profound Medical in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Profound Medical's value of 4 is 20% below this benchmark. Historically, Profound Medical's own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Profound Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.26 — trading 49.2% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Medical Devices & Instruments industry median of 5.00. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Profound Medical (PROF), the current Piotroski F-Score is 4 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $7.26 is trading 49.2% below its estimated GF Value™ of $14.28.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
Piotroski F-Score: 4 (near median its 10-year median of 4.00)
GF Value™: $14.28 vs. price of $7.26 (49.2% below fair value)
Industry Position: 20% below the Medical Devices & Instruments median (#458 of 808)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score
Get the complete analysis for PROF
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
